Clinical Trials Logo

Red-Cell Aplasia, Pure clinical trials

View clinical trials related to Red-Cell Aplasia, Pure.

Filter by:

NCT ID: NCT00005893 Completed - Neutropenia Clinical Trials

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

Start date: June 2000
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the efficacy of bone marrow transplantation using matched related donors in patients with nonmalignant hematologic disorders. II. Determine the quality of life, absence of adverse effects (e.g., graft versus host disease and B cell lymphoproliferative disease), and completeness of recovery of their underlying condition in these patients with this treatment regimen.

NCT ID: NCT00004378 Completed - Thrombocytopenia Clinical Trials

Stem Cell Transplantation (SCT) for Genetic Diseases

Start date: January 1995
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Ascertain whether stem cell transplantation (SCT) is an effective method by which missing or dysfunctional enzymes can be replaced in patients with various inborn errors of metabolism. II. Determine whether clinical manifestations of the specific disease may be arrested or reversed by this treatment.

NCT ID: NCT00004143 Completed - Sickle Cell Anemia Clinical Trials

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

Start date: September 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Although used primarily to treat malignant disorders of the blood, allogeneic stem cell transplantation can also cure a variety of non-cancerous, inherited or acquired disorders of the blood. Unfortunately, the conventional approach to allogeneic stem cell transplantation is a risky procedure. For some non-cancerous conditions, the risks of this procedure outweigh the potential benefits. This protocol is designed to test a new approach to allogeneic stem cell transplantation. It is hoped that this approach will be better suited for patients with non-cancerous blood and bone marrow disorders.